Citigroup Inc Agios Pharmaceuticals, Inc. Put Options Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 12, 2024	BUY	$41.19 - $49.72 $1.06 Million - $1.28 Million	25,700 New	25,700 $1.14 Million
Q1 2024 May 10, 2024	SELL	$21.32 - $34.81 $42,640 - $69,620	-2,000 Reduced 6.94%	26,800 $783,000
Q4 2023 Feb 09, 2024	SELL	$19.97 - $24.53 $597,103 - $733,447	-29,900 Reduced 50.94%	28,800 $641,000
Q3 2023 Nov 09, 2023	BUY	$24.36 - $28.18 $701,568 - $811,584	28,800 Added 96.32%	58,700 $1.45 Million
Q2 2023 Aug 10, 2023	BUY	$21.38 - $29.19 $2,138 - $2,919	100 Added 0.34%	29,900 $846,000
Q1 2023 May 11, 2023	SELL	$21.74 - $30.93 $656,548 - $934,086	-30,200 Reduced 50.33%	29,800 $684,000
Q4 2022 Feb 09, 2023	BUY	$24.81 - $31.52 $258,024 - $327,808	10,400 Added 20.97%	60,000 $1.68 Million
Q3 2022 Nov 10, 2022	BUY	$19.51 - $34.14 $585,300 - $1.02 Million	30,000 Added 153.06%	49,600 $1.4 Million
Q2 2022 Aug 10, 2022	SELL	$17.06 - $31.42 $177,424 - $326,768	-10,400 Reduced 34.67%	19,600 $435,000
Q1 2022 May 12, 2022	BUY	$26.68 - $34.81 $800,400 - $1.04 Million	30,000 New	30,000 $873,000

232

58.1M

403K

469K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.83B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.